Valuation: Exagen Inc.

Market Cap 161M 139M 130M 119M 225M 15.28B 228M 1.52B 598M 7.64B 603M 590M 25.32B P/E 2026 *
-10.2x
P/E 2027 * -13.2x
Enterprise Value 161M 139M 130M 119M 225M 15.28B 228M 1.52B 598M 7.64B 603M 590M 25.32B EV / Sales 2026 *
2.17x
EV / Sales 2027 * 1.98x
Free-Float
57.69%
Yield 2026 *
-
Yield 2027 * -
1 day+3.10%
1 week+52.87%
Current month+46.80%
1 month+46.48%
3 months+115.21%
6 months+97.92%
Current year+9.38%
1 week 4.38
Extreme 4.3801
7.1
1 month 4.05
Extreme 4.05
7.1
Current year 2.59
Extreme 2.59
7.1
1 year 2.59
Extreme 2.59
12.23
3 years 1.3
Extreme 1.3003
12.23
5 years 1.3
Extreme 1.3003
14.9
10 years 1.3
Extreme 1.3003
29.86
Manager TitleAgeSince
Chief Executive Officer 41 17/10/2022
Director of Finance/CFO 57 01/09/2024
Chief Tech/Sci/R&D Officer - 23/06/2025
Director TitleAgeSince
Chairman 72 19/01/2023
Director/Board Member 63 30/07/2019
Director/Board Member 56 17/06/2021
Date Insider Type Main position Quantity % Market Cap.
24/02/26 Sell

Chief Executive Officer

11,430 0.0504%
24/02/26 Sell

Chief Financial Officer

1,584 0.0070%
16/10/25 Sell

Chief Executive Officer

31,787 0.1445%
Change 5-day change 1-year change 3-year change Capi.($)
+3.10%+52.87%-25.03%+164.94% 161M
-0.21%+8.19%+95.99%+438.26% 39.33B
+0.52%+2.22%+19.16%+45.87% 25.4B
-0.04%-1.16%-20.37%-34.68% 7.76B
-3.12%+5.82%+20.92%+101.99% 5.27B
+2.49%+2.94%+20.54%+62.91% 3.32B
-1.40%+9.77%-34.45%+879.13% 2.08B
-3.44%+3.01%+179.89%-1.19% 2.02B
+0.54%+1.39%-9.53%-59.36% 1.91B
+7.57%+17.63%+22.29%-14.98% 1.79B
Average +0.60%+10.73%+26.94%+158.29% 8.9B
Weighted average by Cap. +0.02%+5.51%+51.57%+231.33%

Financials

2026 *2027 *
Net sales 73.89M 64M 59.66M 54.87M 104M 7.03B 105M 701M 275M 3.52B 278M 271M 11.64B 81.28M 70.39M 65.62M 60.35M 114M 7.73B 115M 771M 303M 3.87B 305M 299M 12.81B
Net income -15.83M -13.71M -12.78M -11.76M -22.2M -1.51B -22.44M -150M -58.96M -753M -59.47M -58.16M -2.49B -12.48M -10.81M -10.08M -9.27M -17.5M -1.19B -17.7M -118M -46.48M -594M -46.88M -45.85M -1.97B
Net Debt - -
Logo Exagen Inc.
Exagen Inc. is a provider of autoimmune diagnostics focused on transforming care for patients with chronic and debilitating autoimmune conditions. The Company is focused on the design, development and commercialization of a portfolio of testing products under its AVISE brand, which allow for the differential diagnosis, prognosis and monitoring of complex rheumatic, autoimmune and autoimmune-related disease including, among others, systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its testing products are supported by two proprietary technologies: its AVISE Lupus platform, which incorporates Cell-Bound Complement Activation Products (CB-CAPs) for diagnosing SLE, and a set of three biomarkers, the t-cell-based CB-CAP TC4d, along with two t-cell antibodies, TIgG, and TIgM (the T-Cell Biomarkers), all of which are incorporated into its AVISE CTD product. The Company’s flagship product, AVISE CTD, enables clinicians to more effectively diagnose complex autoimmune conditions.
Employees
218
Date Price Change Volume
05/08/26 $6.650 +3.10% 1,222,724
04/08/26 $6.450 +37.82% 2,745,988
03/08/26 $4.680 +3.31% 212,105
31/07/26 $4.530 -3.00% 106,474
30/07/26 $4.670 +7.36% 98,936
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
6.650USD
Average target price
9.857USD
Spread / Average Target
+48.23%

Quarterly revenue - Rate of surprise